Show simple item record

dc.contributor.authorBaumert, BG
dc.contributor.authorBrada, M
dc.contributor.authorBernier, J
dc.contributor.authorKortmann, RD
dc.contributor.authorDehing-Oberije, C
dc.contributor.authorCollette, L
dc.contributor.authorDavis, JB
dc.date.accessioned2018-08-30T13:39:44Z
dc.date.issued2008-08
dc.identifier2
dc.identifier.citationRADIOTHERAPY AND ONCOLOGY, 2008, 88 pp. 163 - 172
dc.identifier.issn0167-8140
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2428
dc.identifier.doi10.1016/j.radonc.2008.03.025
dc.description.abstractBackground and purpose: The EORTC trial No. 22972 investigated the role of an additional fractionated stereotactic boost (fSRT) to conventional radiotherapy for patients with high grade gliomas. A quality-assurance (QA) programme was run in conjunction with the study and was the first within the EORTC addressing the quality of a supposedly highly accurate treatment technique such as stereotactic radiotherapy. A second aim was to investigate a possible relation between the clinical results of the stereotactic boost arm and the results of the QA. Materials and methods: The trial was closed in 2001 due to low accrual. In total, 25 patients were randomized: 14 into the experimental arm and 11 into the control arm. Six centres randomized patients, 8 centres had completed the dummy run (DR) for the stereotactic boost part. All participating centres (9) were asked to complete a quality-assurance questionnaire. The DR consisted of treatment planning according to the guidelines of the protocol on 3 different tumour volumes drawn on CT images of a humanized phantom. The SRT technique to be used was evaluated by the questionnaire. Clinical data from patients recruited to the boost arm from 6 participating centres were analysed. Results: There was a full compliance to the protocol requirements for 5 centres. Major and minor deviations in conformality were observed for 2 and 3 centres, respectively. Of the 8 centres which completed the DR, one centre did not comply with the requirements of stereotactic radiotherapy concerning accuracy, dosimetry and planning. Median follow-up and median overall survival were 39.2 and 21.4 months, respectively. Acute and late toxicities of the stereotactic boost were low. One radiation necrosis was seen for a patient who has not received the SRT boost. Three reported serious adverse events were all seizures and probably therapy-related. Conclusions: Overall compliance was good but not ideal from the point of view of this highly precise radiation technique. Survival in the subgroup of patients with small volume disease was encouraging, but the study does not provide sufficient information about the potential value of fSRT boost in patients with malignant glioma.Toxicity due to an additional stereotactic boost of 20 Gy in 4 fractions was low and may be considered as a safe treatment option for patients with small tumours. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
dc.format.extent163 - 172
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER IRELAND LTD
dc.titleEORTC 22972-26991/MRC BR10 trial: Fractionated stereotactic boost following conventional radiotherapy of high grade gliomas - Clinical and quality-assurance results of the stereotactic boost arm
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.radonc.2008.03.025
rioxxterms.licenseref.startdate2008-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRADIOTHERAPY AND ONCOLOGY
pubs.notesaffiliation: Baumert, BG (Reprint Author), GROW Res Inst Growth & Dev, Dept Radiat Oncol MAASTRO, Dr Tanslaan 12, NL-6229 ET Maastricht, Netherlands. Baumert, Brigitta G.; Dehing-Oberije, Cary; Davis, J. Bernard, Univ Zurich Hosp, CH-8091 Zurich, Switzerland. Baumert, Brigitta G., Univ Hosp, MASTRO, Dept Radiat Oncol, Maastricht, Netherlands. Baumert, Brigitta G., Inst Canc Res, Neurooncol Unit, London SW3 6JB, England. Baumert, Brigitta G., Inst Canc Res, Acad Unit Radiotherapy & Oncol, London SW3 6JB, England. Baumert, Brigitta G., Royal Marsden NHS Fdn Trust, London, England. Bernier, Jacques, Clin Genolier, Dept Radiat Oncol, Genolier, Switzerland. Kortmann, Rolf D., Univ Hosp Leipzig, Clin & Policlin Radiat Oncol, Leipzig, Germany. Collette, Laurence, Eortc Data Ctr, Dept Stat, Brussels, Belgium. keywords: quality assurance; dummy run; stereotactic radiotherapy; high grade glioma; stereotactic boost; dose escalation keywords-plus: THERAPY ONCOLOGY GROUP; LYMPH-NODE CHAIN; DUMMY RUN; PHASE-III; RADIATION-THERAPY; COOPERATIVE GROUP; INTERNAL MAMMARY; BREAST-CANCER; GLIOBLASTOMA-MULTIFORME; EUROPEAN ORGANIZATION research-areas: Oncology; Radiology, Nuclear Medicine & Medical Imaging web-of-science-categories: Oncology; Radiology, Nuclear Medicine & Medical Imaging author-email: [email protected] researcherid-numbers: Oberije, Cary/I-4018-2013 orcid-numbers: Oberije, Cary/0000-0003-0749-5117 funding-acknowledgement: National Cancer Institute (Bethesda, Maryland, USA) [5U10-CA11488-27, 5U10CA11488-37]; Schweizerische Krebsliga (Swiss League against Cancer) funding-text: This publication was supported by Grants No. 5U10-CA11488-27 through 5U10CA11488-37 from the National Cancer Institute (Bethesda, Maryland, USA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. This research project was also supported in part by the Schweizerische Krebsliga (Swiss League against Cancer). number-of-cited-references: 37 times-cited: 15 usage-count-last-180-days: 0 usage-count-since-2013: 0 journal-iso: Radiother. Oncol. doc-delivery-number: 350CK unique-id: ISI:000259329900001 da: 2018-08-30
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume88
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record